Skip to main content
. 2017 Jul 13;11(7):e0005680. doi: 10.1371/journal.pntd.0005680

Fig 7. PDE4 inhibitors induce hypermotility in transgenic C. elegans expressing smpde4a.

Fig 7

C. elegans was exposed to 100 μM rolipram, roflumilast or the benzoxaborole compounds 2 and 4, and then worm motility measured. Effects on (A) WT, (B) hypermotile mutant pde4(ce268), (C) transgenic pde4(ce268);smpde4a(a) and (D) transgenic pde4(ce268);smpde4a(b) are shown. Means and standard deviations for motility are normalized over two experiments to DMSO controls; each experiment involved measuring at least 10 worms per treatment. The asterisks in each panel indicate significance by Student’s t-test (*p<0.005; **p<0.0005) relative to the respective DMSO controls. For Panel B, motility was normalized to that recorded for the WT control.